CATX at a glance
Perspective Therapeutics, Inc. (CATX, SEC CIK 728387) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as September 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Perspective Therapeutics, Inc. (CATX) shares worth $131.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Lantheus Alpha Therapy, LLC on September 4, 2026 of 167,149 shares at $3.15 per share.
- In the last 90 days, CATX insiders reported 0 open-market purchases ($0) and 7 open-market sales ($1.6M) on Form 4, a net sale of $1.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$1.6M
- 13F holders
- 23 funds
- $131.8M · +0 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Risk Factors section not provided; supplied text begins with Item 2 and contains no risk disclosures
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable from the provided text
AI summary of the CATX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Exhibit 99.1 provides Perspective Therapeutics’ corporate presentation for investor reference
- Filing dated October 1, 2026, signed by CFO Joel Sendek
Item EX-99.1: Item EX-99.1
- Investor presentation highlights three clinical-stage radiopharmaceutical programs, each targeting distinct cancers with data expected in 2026
- VMT-α-NET Phase 1/2a analysis includes 68 treated patients, supporting potential registration study at the current dose
Item 8.01: Other Events
- Item 8.01 references Exhibit 99.1, containing a press release likely providing the material event details
- Filing signed by CEO Johan (Thijs) Spoor on September 14, 2026
Item EX-99.1: Item EX-99.1
- Merck collaboration adds Keytruda to PSV359’s Phase 1/2a trial in FAP-α-positive solid tumors
- Merck supplying pembrolizumab at no cost, limiting combination-study drug expense for Perspective
Item 8.01: Other Events
- Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation, potentially relevant for updated strategy and investor messaging
- Filing signed September 8, 2026 by CFO Joel Sendek
Item EX-99.1: Item EX-99.1
- Investor presentation outlines three independent clinical-stage programs, each targeting distinct cancers with data expected in 2026
- VMT-α-NET Phase 1/2a data cover 68 treated patients, supporting potential registration study at the current dose
AI summaries of CATX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CATX
Don't miss the next CATX filing
- Alerts as it files. A push when CATX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CATX, by share count.
- Ask anything. An AI agent that reads every CATX filing and answers with sources.
CATX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | Sell | Sep 4, 2026 | 167,149 | $3.15 |
| Lantheus Alpha Therapy, LLC | Sell | Sep 3, 2026 | 80,783 | $3.11 |
| Lantheus Alpha Therapy, LLC | Sell | Sep 2, 2026 | 42,129 | $3.11 |
| Lantheus Alpha Therapy, LLC | Sell | Sep 1, 2026 | 35,769 | $3.12 |
| Lantheus Holdings, Inc. | Sell | Sep 1, 2026 | 35,769 | $3.12 |
| Lantheus Alpha Therapy, LLC | Sell | Aug 31, 2026 | 78,145 | $3.14 |
| Lantheus Holdings, Inc. | Sell | Aug 31, 2026 | 78,145 | $3.14 |
| Martinez Maria E | A | Mar 2, 2026 | 50,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Gross Profit | $1.4M | - | - |
| Operating Income | - | -$90.9M | -$113.6M |
| Net Income | -$46.5M | -$79.3M | -$103.1M |
| Balance Sheet | |||
| Total Assets | $97.9M | $341.1M | $267.0M |
| Equity | $75.2M | $290.7M | $207.0M |
| ROE | -61.9% | -27.3% | -49.8% |
| Per Share | |||
| EPS | - | $-1.23 | $-1.40 |
| Cash Flow | |||
| Operating CF | -$36.9M | -$18.3M | -$82.5M |
| CapEx | $1.1M | $54.4M | $12.7M |
Source: XBRL data in Perspective Therapeutics, Inc. (CATX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CATX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $131.8M |
| Q1 2026 | 23 | $119.9M |
| Q4 2025 | 21 | $51.7M |
| Q3 2025 | 19 | $95.1M |
| Q2 2025 | 20 | $92.5M |
| Q1 2025 | 16 | $40.2M |
| Q4 2024 | 13 | $55.1M |
| Q3 2024 | 8 | $47.2M |
- BlackRock+4.15M (+78%)
- State Street Corp+2.92M (+93%)
- Millennium Management+865.2K (+21%)
- Dimensional Fund Advisors+624.0K (+139%)
- Two Sigma Investments+553.0K (+55%)
- Morgan Stanley−1.07M (-36%)
- Invesco Ltd−178.5K (-77%)
- PNC Financial Services−1 (-0%)
- U.S. Bancorp−344
Source: 13F-HR filings on SEC EDGAR (aggregated from 143 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CATX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| SC 13G | Jul 29, 2026 | - | - | |
| SC 13G | Jul 20, 2026 | - | - | |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| SC 13G | Jun 30, 2026 | - | - | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 8-K | May 27, 2026 | - | Analysis | |
| 8-K | May 22, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Apr 20, 2026 | - | Analysis | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CATX SEC filings: frequently asked questions
Are CATX insiders buying or selling?
In the last 90 days, Perspective Therapeutics, Inc. (CATX) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $1.6 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CATX stock?
As of June 30, 2026, the largest Perspective Therapeutics, Inc. (CATX) holders among the 13F filers tracked by SignalX were BlackRock ($32.4 million), State Street Corp ($20.6 million), Millennium Management ($16.7 million), Vanguard Capital Management LLC ($15.1 million), Citadel Advisors LLC ($13.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did CATX report in its latest 8-K?
Perspective Therapeutics, Inc. (CATX) filed an 8-K on October 1, 2026 reporting Item 8.01 (Other Events). Exhibit 99.1 provides Perspective Therapeutics’ corporate presentation for investor reference.
What are the latest CATX SEC filings?
Perspective Therapeutics, Inc. (CATX) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on September 8, 2026.
What is CATX's SEC CIK number?
Perspective Therapeutics, Inc. (CATX)'s SEC Central Index Key (CIK) is 728387. EDGAR lists every CATX filing under that number.
Ask anything about CATX
The research agent reads CATX's filings, financials, insider trades and 13F holders, then answers with sources.